High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect
- PMID: 1619410
- PMCID: PMC1014899
- DOI: 10.1136/jnnp.55.6.450
High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect
Abstract
The integrity of the blood-brain barrier (BBB) in multiple sclerosis (MS) was monitored by serial gadolinium-(Gd)-DTPA enhanced MRI during and after the treatment of acute relapses with a three day course of high dose intravenous methylprednisolone (IVMP). During treatment there was a rapid reduction of BBB abnormalities in 96% of enhancing lesions. In spite of sustained clinical improvement, many lesions re-enhanced within a few days of stopping IVMP, and new lesions frequently appeared within one month. It is possible that the rapid, albeit transient, reversal of BBB abnormalities contributes to the accelerated recovery from relapses associated with IVMP treatment.
Similar articles
-
A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS.Mult Scler. 2014 May;20(6):717-25. doi: 10.1177/1352458513508835. Epub 2013 Oct 21. Mult Scler. 2014. PMID: 24144876 Clinical Trial.
-
Quantitative MRI changes in gadolinium-DTPA enhancement after high-dose intravenous methylprednisolone in multiple sclerosis.Neurology. 1991 Aug;41(8):1219-22. doi: 10.1212/wnl.41.8.1219. Neurology. 1991. PMID: 1866009
-
Randomized trial comparing two different high doses of methylprednisolone in MS: a clinical and MRI study.Neurology. 1998 Jun;50(6):1833-6. doi: 10.1212/wnl.50.6.1833. Neurology. 1998. PMID: 9633736 Clinical Trial.
-
Mitoxantrone: a review of its use in multiple sclerosis.CNS Drugs. 2004;18(6):379-96. doi: 10.2165/00023210-200418060-00010. CNS Drugs. 2004. PMID: 15089110 Review.
-
The effects of high-dose methylprednisolone on gadolinium-enhanced magnetic resonance imaging and cerebrospinal fluid measurements in multiple sclerosis.J Neuroimmunol. 1992 Oct;40(2-3):265-72. doi: 10.1016/0165-5728(92)90142-8. J Neuroimmunol. 1992. PMID: 1430156 Review.
Cited by
-
Inflammation and Oxidative Stress in Multiple Sclerosis: Consequences for Therapy Development.Oxid Med Cell Longev. 2020 May 12;2020:7191080. doi: 10.1155/2020/7191080. eCollection 2020. Oxid Med Cell Longev. 2020. PMID: 32454942 Free PMC article. Review.
-
Multiple sclerosis therapy. A practical guide.Drugs. 1995 Feb;49(2):200-12. doi: 10.2165/00003495-199549020-00005. Drugs. 1995. PMID: 7729328 Review.
-
Development, maintenance and disruption of the blood-brain barrier.Nat Med. 2013 Dec;19(12):1584-96. doi: 10.1038/nm.3407. Epub 2013 Dec 5. Nat Med. 2013. PMID: 24309662 Free PMC article. Review.
-
Dexamethasone potentiates in vitro blood-brain barrier recovery after primary blast injury by glucocorticoid receptor-mediated upregulation of ZO-1 tight junction protein.J Cereb Blood Flow Metab. 2015 Jul;35(7):1191-8. doi: 10.1038/jcbfm.2015.38. Epub 2015 Mar 11. J Cereb Blood Flow Metab. 2015. PMID: 25757751 Free PMC article.
-
Current Update on Transcellular Brain Drug Delivery.Pharmaceutics. 2022 Dec 5;14(12):2719. doi: 10.3390/pharmaceutics14122719. Pharmaceutics. 2022. PMID: 36559214 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical